Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tisotumab Vedotin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 27, 2020

            Details:

            Results from the phase 2 innovaTV 204 study evaluating tisotumab vedotin in patients with recurrent or metastatic cervical cancer will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 2X-121

            Therapeutic Area: Oncology Product Name: 2X-121

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: 2X Oncology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition July 13, 2020

            Details:

            The Company now has 100 % ownership of 2X-121, which is being clinically developed as an anti-cancer therapeutic, as well as being tested as an anti-viral agent against COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tisotumab Vedotin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2020

            Details:

            Results from innovaTV 204 evaluating tisotumab vedotin showed that a 24 percent confirmed objective response rate (ORR) by independent central review (95% Confidence Interval: 15.9% - 33.3%) with a median duration of response (DOR) of 8.3 months.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cisplatin

            Therapeutic Area: Oncology Product Name: LiPlaCis

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Smerud Medical Research

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement June 29, 2020

            Details:

            Oncology Venture has entered a definitive agreement, out-licensing two clinical pipeline assets, LiPlaCis® and 2X-111, to Smerud Medical Research International for further clinical and commercial development.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SCO-101,Taxane

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Innovation Fund Denmark

            Deal Size: $0.7 million Upfront Cash: Undisclosed

            Deal Type: Funding February 19, 2020

            Details:

            The grant of DKK 5 million from Innovation Fund Denmark is earmarked for the clinical phase II development of SCO-101 in metastatic pancreatic cancer.